QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx

  • U.S. government awards $3.4 million to boost production of PCR tests for NeuMoDx 96 and 288 clinical integrated systems
  • Award follows $600,000 contract to increase output of enzymatic reagents and reagent products

GERMANTOWN, Md. & HILDEN, Germany--()--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it had won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems, an important step to support laboratory testing as the COVID-19 pandemic continues.

QIAGEN was awarded a $3.4 million contract by the U.S. Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), to expand production capacity for COVID-19 tests running on NeuMoDx instruments at its site in Ann Arbor, Michigan. The platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests. By the end of March 2022, QIAGEN plans to scale up production to more than 16 million tests per year, up from the current level of about 10 million.

This contract follows a DOD announcement in August 2021 that it and HHS had awarded QIAGEN a contract for approximately $600,000 to expand production capacity for chemical reagents. The QIAGEN site at Beverly, Massachusetts, is the center of the company’s reagent manufacturing for other Original Equipment Makers (OEMs) in the molecular testing market, including for COVID-19 tests.

“These U.S. government contracts and capacity expansions are a testament to the crucial role of PCR testing in the fight against COVID-19 and their increasing value to improving outcomes to patients,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development. “QIAGEN is increasing its flexible production capabilities to ensure the availability of our PCR testing solutions for COVID-19 and other diseases where they are needed most.”

For more information about QIAGEN’s Sample to Insight technologies, please visit www.qiagen.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2021, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Category: Corporate

Source: QIAGEN N.V.

Contacts

QIAGEN

Investor Relations
John Gilardi, +49 2103 29 11711
Phoebe Loh, +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676
e-mail: pr@QIAGEN.com

Release Summary

QIAGEN receives U.S. Department of Defense contract to further expand production capacity for NeuMoDx.

$Cashtags

Contacts

QIAGEN

Investor Relations
John Gilardi, +49 2103 29 11711
Phoebe Loh, +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676
e-mail: pr@QIAGEN.com